SABCS 2025 curtain raiser

New data reinforces MammaPrint® and BluePrint® tests’ expanding clinical utility to optimize treatment selection.

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – November 25, 2024 – Agendia®, Inc., announced today that new data on its early-stage breast cancer genomic tests and their ability to inform treatment selection decisions will be presented at the San Antonio Breast Cancer Symposium (SABCS) , taking place in San Antonio, TX, December 10th – 13th, 2024. 

The presented data highlights Agendia’s continued focus on expanding clinical utility of the tests and optimizing breast cancer management throughout the patient’s treatment journey. These studies further enhance robust body of clinical research supporting the clinical utility of Agendia’s MammaPrint and BluePrint in providing reliable guidance for therapeutic decisions in early-stage breast cancer.

Five Agendia abstracts have been accepted, including two poster spotlight presentations and one late-breaking poster. The following are details of the abstracts that have been accepted:

Poster Spotlight Presentations:

  • MammaPrint® and BluePrint® Predict Pathological Response to Neoadjuvant Chemotherapy in Patients with HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX.

Authors: O’Shaughnessy, J., et al. 

Session: Poster Spotlight Session 4: Prediction of Chemotherapy Response

Date/Time: Wednesday, December 11 | 7:00 AM – 8:30 AM CST

Abstract #: 2091

  • Association of MammaPrint® with Gene Expression Pathways Predictive of Resistance to Cyclin Dependent Kinase Inhibition

Authors: Brufsky, A., et al.

Session: Poster Spotlight Session 2: Personalizing CDK 4/6 Inhibitor Therapy for Patients with Metastatic Breast Cancer: Survival, QOL and Biomarkers

Date/Time: Thursday, December 12 | 7:00 AM – 8:30 AM CST

Abstract #: SESS-2068

Poster Presentations:

  • Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine – Biology is Still King

Authors: Rahman, R., et al. 

Session: Poster Session 1

Date/Time: Wednesday, December 11 | 12:30 PM – 2 PM CST

Abstract #: 1879

  • FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients with Early-Stage Breast Cancer 

Authors: Maganini, R.

Session: Poster Session 2

Date/Time: Wednesday, December 11 | 5:30 PM – 7:00 PM CST

Abstract #: 2160

Late-Breaking Poster:

  • Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early-Stage Breast Cancer Revealed by the FLEX Registry of Real-World Data 

Authors: Brufsky, A., et al.

Session: Poster Session 2

Date/Time: Wednesday, December 11 | 5:30 PM – 7:00 PM CST

Abstract #:  3660

Agendia Product Theatre

In addition, William Audeh, MD, MS, Chief Medical Officer of Agendia, will be presenting at Agendia’s Product Theater session, titled “How Can Genomic Information From A Single Core Biopsy Sample Inform Multiple Therapy Decisions For Early-Stage ER+ Breast Cancer?,” demonstrating how MammaPrint and BluePrint can inform early-stage ER+ breast cancer treatment decisions. The educational session will take place on December 11th at 5:30 PM – 6:30 PM CST.

Registration details can be found here. 

More information about the full program can be found at the SABCS 2024 website.

Media Contact
Terri Clevenger
ICR Healthcare PR
Tel: 203.682.8297
Terri.Clevenger@ICRHealthcare.com